NCT03848481View on ClinicalTrials.gov

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Prader-Willi Syndrome
Interventions
DRUG

CBDV Compound

CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC

DRUG

Placebo

Placebo oral solution contains matching excipients.

Trial Locations (1)

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

Sponsors

Collaborators (1)

GW Pharmaceuticals Ltd
All Listed Sponsors
collaborator

Foundation for Prader-Willi Research

OTHER

collaborator

GW Pharmaceuticals Ltd

INDUSTRY

lead

Montefiore Medical Center

OTHER